drugset / Trial / NCT06178211
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in patients with resectable esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2023-12
- Primary completion
- 2025-03
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |